Cancer Immunology Immunotherapy,
Год журнала:
2025,
Номер
74(5)
Опубликована: Апрель 5, 2025
This
study
aimed
to
identify
clinical
factors
and
develop
a
predictive
model
for
pathological
complete
response
(pCR)
major
(MPR)
in
non-small
cell
lung
cancer
(NSCLC)
patients
receiving
neoadjuvant
chemotherapy
combined
with
immune
checkpoint
inhibitors
(ICIs).
Cases
meeting
inclusion
criteria
were
divided
into
high-
low-risk
groups
according
75
indicators
based
on
tenfold
LASSO
selection.
Logistic
regression
was
employed
analyze
both
pCR
MPR.
The
accuracy
of
the
nomograms
assessed
using
time-dependent
area
under
curve
(AUC).
A
total
297
from
four
multiple
centers
included
study,
212
assigned
training
set
85
testing
set.
AUC
determined
prediction
(training:
0.97;
testing:
0.88)
MPR
0.98;
0.81).
Significant
associations
observed
between
preoperative
tumor
maximum
diameter,
standardized
uptake
value
(SUVmax),
changes
SUVmax,
percentage
reduction,
baseline
prostate-specific
antigen
(TPSA)
(P
<
0.001).
application
including
non-invasive
imaging
hematology
can
help
clinicians
obtain
higher
ability
predict
NSCLC
patient's
remission,
effect
is
better
than
that
alone.
These
findings
could
guide
personalized
treatment
strategies
this
patient
population.
npj Precision Oncology,
Год журнала:
2020,
Номер
4(1)
Опубликована: Дек. 1, 2020
Abstract
Neoadjuvant
immunotherapy
provides
a
unique
opportunity
for
understanding
therapeutic
responses.
We
analyzed
pathologic
responses
in
surgical
specimens
obtained
from
31
squamous
non-small
cell
lung
cancer
(NSCLC)
patients
receiving
neoadjuvant
anti-PD-1
treatment.
Fifteen
(48.4%)
achieved
complete
response
(pCR)
or
major
(MPR).
Among
them,
seven
(46.7%)
were
assessed
as
radiological
partial
and
eight
(53.3%)
stable
disease.
20
with
pathologically
identified
tumor
beds
lymph
nodes
(LNs),
10
six
pCR/MPR
primary
tumors
paired
LNs,
respectively.
pCR
was
6/19
N1
1/7
N2
nodes.
Residual
viable
(RVT)
cells
8/9
MPR
had
100%
immune-activated
phenotype,
while
median
of
80%
RVT
nonresponse
presented
immune-excluded/desert
phenotype.
These
findings
demonstrated
that
assessment
both
LNs
may
be
important
surrogate
assessing
immunotherapeutic
efficacy.
Abstract
Anti-programmed
cell
death-1
(PD-1)/programmed
death
ligand-1
(PD-L1)
antibodies
are
administered
in
varied
human
cancer
types.
The
expression
of
PD-L1
within
tumor
cells
has
been
identified
as
a
predictive
marker,
although
assessing
its
benefitted
only
patients
with
non-small
lung
(NSCLC)
or
head
and
neck
cancer.
Whereas,
more
than
75%
the
NSCLC
showing
partial
response
to
PD-1
blockade
therapy
experienced
long-term
survival
for
5-years
Thus,
identifying
responders
at
early
phase
after
initiation
is
clinical
importance.
2-deoxy-2-[fluorine-18]
fluoro-D-glucose
(
18
F-FDG)
on
positron
emission
tomography
(PET)
can
evaluate
any
shrinkage
by
metabolic
volume
an
earlier
conventional
modalities
such
computed
(CT).
While
several
reports
describe
correlation
F-FDG
uptake
rate
cells,
it
remains
be
delineated
whether
this
determined
glucose
metabolism
hypoxia
associated
status
immune
microenvironment,
including
PD-L1.
Moreover,
details
relationship
between
still
unclear.
Therefore,
we
reviewed
significance
PET
predictor
efficacy
therapy,
correlating
PD-L1,
neoplasms.
Biomarker Research,
Год журнала:
2022,
Номер
10(1)
Опубликована: Апрель 18, 2022
Abstract
Anti-programmed
death-1
(PD-1)/programmed
death-ligand
1
(PD-L1)
immunotherapy
has
dramatically
changed
the
therapeutic
landscape
of
inoperable
non-small
cell
lung
cancer
(NSCLC),
and
been
included
in
first-line
treatments.
Sintilimab
is
a
domestic
anti-PD-1
monoclonal
antibody
China
that
received
approvals
from
National
Medical
Products
Administration
to
treat
classical
Hodgkin’s
lymphoma,
hepatocellular
carcinoma,
squamous
non-squamous
NSCLC.
In
prospective
clinical
study
we
led,
neoadjuvant
sintilimab
led
major
complete
pathologic
responses,
which
are
recommended
as
surrogate
endpoints
for
immunotherapy;
however,
its
effect
remains
inconclusive
pulmonary
ground
glass
nodules.
Meanwhile,
combination
plans
seem
more
likely
be
satisfying
options.
Specifically,
plus
platinum-based
chemotherapy
conferred
better
anti-tumor
efficacy
benefits
compared
alone,
their
approval
acceptance
biological
license
application
US.
Besides,
with
other
plans,
such
docetaxel,
cytokine-induced
killer
immunotherapy,
radiation
therapy,
anlotinib
have
also
shown
promising
efficacy,
acceptable
toxicities,
therefore
worth
further
exploration.
addition,
several
trials
on
NSCLC
at
our
center
ongoing.
general,
combinatorial
were
effective
well
tolerated,
but
treatment
requires
appropriate
timing;
responses
can
while
biomarkers
warranted.
This
provides
an
overview
sintilimab-based
NSCLC,
may
support
investigation
future
trials.
Abstract
Objective
To
evaluate
the
potential
utility
of
18
F-FDG
PET/CT
to
assess
response
neoadjuvant
immunochemotherapy
in
patients
with
resectable
NSCLC,
and
ability
screen
who
may
benefit
from
immunochemotherapy.
Methods
Fifty
one
NSCLC
(stage
IA–IIIB)
were
analyzed,
received
two-three
cycles
was
carried
out
at
baseline(scan-1)
prior
radical
resection(scan-2).
SULmax,
SULpeak,
MTV,
TLG,
T/N
ratio,
ΔSULmax%,ΔSULpeak%,
ΔMTV%,
ΔTLG%,ΔT/N
ratio%
calculated.
responses
classified
using
PERCIST.
We
then
compared
RECIST
1.1
PERCIST
criteria
for
assessment.With
surgical
pathology
primary
lesions
as
gold
standard,
correlation
between
metabolic
parameters
major
pathologic
(MPR)
analyzed.
All
treatment
correlated
PFS
OS.
Results
In
total
fifty
patients,
MPR
achieved
25(49%,
25/51)
after
therapy.
The
Scan-1
not
MPR.The
degree
pathological
regression
negatively
ratio
scan-2,
percentage
changes
ΔSULmax%,
ΔSULpeak%,
ΔMTV%,ΔTLG%,ΔT/N
therapy
(
p
<
0.05).
According
PERCIST,
36
(70.6%,
36/51)
showed
PMR,
12
patients(23.5%,
12/51)
had
stable
disease(SMD),
3
patients(5.9%,
3/51)
progressive
disease
(PMD).
ROC
indicated
that
all
scan-2
predict
non-MPR,
SULmax
best
differentiation
ability.The
accuracy
no
statistical
significance(
=
0.91).
On
univariate
analysis,
ΔMTV%
has
highest
PFS.
Conclusions
Metabolic
by
can
NSCLC.
significantly
Journal of Clinical Medicine,
Год журнала:
2021,
Номер
10(21), С. 5160 - 5160
Опубликована: Ноя. 3, 2021
Immunotherapy
with
checkpoint
inhibitors
has
prompted
a
major
change
not
only
in
cancer
treatment
but
also
medical
imaging.
In
parallel
the
implementation
of
new
drugs
modulating
immune
system,
response
criteria
have
been
developed,
aiming
to
overcome
clinical
drawbacks
related
new,
unusual,
patterns
characterizing
both
solid
tumors
and
lymphoma
during
course
immunotherapy.
The
acknowledgement
pseudo-progression,
hyper-progression,
immune-dissociated
so
forth,
become
mandatory
for
all
imagers
dealing
this
scenario.
A
long
list
acronyms,
i.e.,
irRC,
iRECIST,
irRECIST,
imRECIST,
PECRIT,
PERCIMT,
imPERCIST,
iPERCIST,
depicts
enormous
effort
made
by
radiology
nuclear
medicine
physicians
last
decade
optimize
imaging
parameters
better
prediction
benefit
immunotherapy
regimens.
Quite
frequently,
combination
clinical-laboratory
data
findings
tested,
proving
ability
stratify
patients
into
various
risk
groups.
next
steps
necessarily
require
large
scale
validation
most
robust
criteria,
as
well
immune-targeting
tracers
immuno-PET
or
exploitation
radiomics
artificial
intelligence
complementary
tools
administration.
For
present
review
article,
summary
PET/CT
role
monitoring
will
be
provided.
By
scrolling
types
applied
reader
obtain
necessary
information
understanding
potentials
limitations
modality
setting.
